Please assess the completion status of the following clinical trial:

Trial Title: Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women between the ages of 30 and 80 years inclusive~2. T2DM diagnosed by a physician \</= 5 years prior to enrolment~3. Negative for anti-glutamic acid decarboxylase (anti-GAD) antibodies~4. On either no anti-diabetic medication or on metformin monotherapy, with no change in dose/regimen within 4 weeks prior to enrolment~5. A1c at screening between 5.5% and 9.0% inclusive if on metformin, or between 6.0% and 9.5% inclusive if on no oral anti-diabetic medication~6. BMI \>/= 23 kg/m2~7. Negative pregnancy test at recruitment for all women with childbearing potential~Exclusion Criteria:~1. Current anti-diabetic treatment with insulin, sulfonylurea, thiazolidinedione, alpha-glucosidase inhibitor, glucagon-like peptide-1 (GLP-1) agonist or dipeptidyl peptidase-4 inhibitor~2. Type 1 diabetes or secondary forms of diabetes~3. History of hypoglycemia unawareness or severe hypoglycemia requiring assistance~4. Any major illness with a life expectancy of \<5 years~5. Hypersensitivity to insulin, metformin or the formulations of these products~6. Renal dysfunction as evidenced by estimated glomerular filtration rate (eGFR) \<50 ml/min~7. Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, previous liver transplant) or transaminases \>2.5 X upper limit of normal~8. History of congestive heart failure~9. Excessive alcohol consumption, defined as \>14 alcoholic drinks per week for males and \>9 alcoholic drinks per week for females~10. Unwillingness to administer insulin therapy or perform capillary blood glucose monitoring at least 4 times per day while receiving IIT~11. Pregnancy or unwillingness to use reliable contraception. Women should not be planning pregnancy for the duration of the study or the first 3 months after the study. Reliable contraception includes birth control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or condoms with spermicide.~12. Non-adherence to the induction phase or any factor likely to limit adherence to the study protocol, in the opinion of the investigator

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metformin alone (Type: ACTIVE_COMPARATOR): After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
- Metformin + Intermittent Insulin Therapy (Type: EXPERIMENTAL): After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy, initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months). Participants will stop their metformin for 2 weeks every 3 months, during which time they will receive intermittent intensive insulin therapy for 2 weeks. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months.

Based on this trial design, predict the completion outcome and termination type (if applicable).